CD34+ cell selection significantly improves GvHD-free survival in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, specific information regarding long-term prognosis and risk factors for late mortality after CD34+ cell-selected allo-HSCT is lacking. We conducted a single-center landmark analysis in 276 patients alive without relapse 1 year after CD34+ cell-selected allo-HSCT for AML (n = 164), ALL (n = 33) or myelodysplastic syndrome (n = 79). At 5 years' follow-up after the 1-year landmark (range 0.03-13 years), estimated relapse-free survival (RFS) was 73% and overall survival (OS) 76%. The 5-year cumulative incidence of relapse and non-relapse mortality (NRM) were 11% and 16%, respectively. In multivariate analysis, Hematopoietic Cell Transplantation Comorbidity Index score ⩾ 3 correlated with marginally worse RFS (hazard ratio (HR) 1.78, 95% confidence interval (CI) 0.97-3.28, P = 0.06) and significantly worse OS (HR 2.53, 95% CI 1.26-5.08, P = 0.004). Despite only 24% of patients with acute GvHD within 1 year, this also significantly correlated with worse RFS and OS, with increasing grades of acute GvHD associating with increasingly poorer survival on multivariate analysis (Po0.0001). Of 63 deaths after the landmark, GvHD accounted for 27% of deaths and was the most common cause of late mortality, followed by relapse and infection. Although prognosis is excellent for patients alive without relapse 1 year after CD34+ cell-selected allo-HSCT, risks of late relapse and NRM persist, particularly due to GvHD.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established therapy for hematologic malignancies, including relapsed/refractory or high-risk AML or ALL and myelodysplastic syndrome (MDS). Yet, transplant recipients remain at risk of relapse, late complications and non-relapse mortality (NRM). In particular, GvHD is a potentially devastating complication. The use of T-cell depletion (TCD) of allografts by CD34+ cell selection has improved GvHD-free survival in acute leukemia and MDS without the need for post-transplant immunosuppression and without increased risk of relapse. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Previous analyses of multicenter data reported to the Center for International Blood and Marrow Transplant Research to evaluate prognosis for recipients of myeloablative allo-HSCT, who survive without relapse past the early posttransplant period, have found that long-term survival for these patients is excellent. 11, 12 Possible risk factors for late mortality include chronic GvHD, relapsed/ refractory disease and poor performance status. These registry studies included patients who received both T-cell replete and TCD allografts, which in many cases employed older methods of TCD. Prognostic information is lacking for patients who undergo TCD transplantation using contemporary techniques and survive without relapse past the early post-HSCT period. This study therefore focused on long-term prognosis in these patients to identify barriers to long-term survival after CD34+ cell-selected allo-HSCT.
PATIENTS AND METHODS Patients
The study included adult recipients of first allo-HSCT with a CD34+ cellselected PBSC transplant at Memorial Sloan Kettering Cancer Center for AML, MDS or ALL between February 2000 and June 2013. All patients and donors provided written informed consent for treatment. The Memorial Sloan Kettering Cancer Center Institutional Review and Privacy Board approved this retrospective study. High-resolution DNA-specific oligonucleotide typing characterized HLA-A, -B, -C, -DRB1 and -DQB1 loci. Clinical outcomes, including acute and chronic GvHD, relapse, and causes of death, were captured in real time per standard clinical practice. busulfan 0.8 mg/kg/dose every 6 h for 10 or 12 doses, melphalan 70 mg/m 2 /day for 2 doses and fludarabine 25 mg/m 2 /day for 5 doses, or clofarabine 20 mg/m2/day for 5 days, melphalan 70 mg/m2/day for 2 days and thiotepa 5 mg/kg/day for 2 days (or 10 mg/kg for 1 day), each regimen specified by institutional protocol 10-050 (NCT01119066). 6 CD34+ cell selection of PBSCs was accomplished by positive selection of CD34+ stem cells using the ISOLEX 300i Magnetic Cell Separator (Baxter, Deerfield, IL, USA) followed by sheep RBC rosette depletion or, beginning in 2006 and exclusively after May 2010, using the CliniMACS CD34 Reagent System (Miltenyi Biotech, Gladbach, Germany) without the need for additional sheep RBC rosette depletion of residual T cells. Allografts were infused within 24-48 h of completion of cytoreduction. Patients received no pharmacologic GvHD prophylaxis. Graft rejection prophylaxis consisted 
Study definitions and statistical analysis
GvHD was diagnosed clinically and confirmed histologically where appropriate. Acute and chronic GvHD were evaluated using International Bone Marrow Transplant Registry 13 and National Institutes of Health consensus criteria, 14 respectively. Cause of death was determined using the algorithm devised by Copelan et al., 15 which employs a hierarchy of events to identify the underlying cause of death: for instance, if a patient dies of GvHD after donor lymphocyte infusion for relapse, relapse is the primary cause of death; if a patient dies of infection while on treatment for GvHD, GvHD is the cause of death. 15 Disease risk and relapse were categorized using standard guidelines. [16] [17] [18] In AML, as evaluation of molecular features including FLT3, NPM1, CEBPA and c-kit mutational analysis became standard practice only during the course of the period studied, patients were stratified by cytogenetic features with incorporation of molecular data where available. Kaplan-Meier methods estimated overall survival (OS) and relapse-free survival (RFS). Relapse and NRM were estimated with cumulative incidence functions. Given the small number of patients with GvHD onset after the landmark, incidence of GvHD was characterized descriptively. All patients including those who underwent second allo-HSCT were included in accounts of GvHD. Association of characteristics with RFS and OS was evaluated using Cox regression. Variables significant to P ⩽ 0.05 were evaluated for association in a multivariable Cox regression model. Association between donor type and GvHD by 1 year was assessed using the χ 2 -test. Competing risks analysis was performed using R version 3.2.4 (www.R-project.org). All other statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
RESULTS

Patient characteristics
A total of 416 patients underwent CD34-selected allogeneic PBSC transplant for AML, MDS or ALL. Of these, 276 patients were alive without relapse at the designated 1-year landmark and were included in the analysis. Of those excluded, 114 had died before 1 year; the remaining 26 were alive with relapse at 1 year. Table 1 summarizes patient and transplant characteristics. Median CD34+ cell dose was 7.6 × 10 6 cells/kg (range 0.6-31.2 × 10 6 ) and median CD3+ T-cell dose was 1.9 × 10 3 cells/kg (range 0-63.0 × 10 3 ). Twenty-one patients (8%) received donor lymphocyte infusion before the 1-year landmark, in 17 cases (81%) for mixed chimerism without relapse, in 2 cases for minimal residual disease and in 2 cases to promote immune reconstitution in the setting of severe viral infection (JC virus and HHV-6). Nine patients in the landmark cohort (3%) had received a CD34-selected cell boost for poor graft function or secondary graft failure. Table 1 summarizes disease-specific characteristics. In AML, 71% of patients were transplanted in CR1. The majority of patients had poor-(n = 51, 31%) or intermediate-risk (n = 95, 58%) disease. Mutations were present in 19/62 patients (31%) analyzed for FLT3 (internal tandem duplication or tyrosine kinase domain variant), 4/46 (9%) for isolated NPM1 mutations and 0/22 for CEBPA mutations. Thirteen (8%) had c-kit mutation testing; one of these (8%) was positive, in conjunction with inversion of chromosome 16. Eighty-two percent of patients with MDS underwent allo-HSCT with morphologic evidence of disease, although the majority of patients (67%) had fewer than 5% blasts. In ALL, 82% of patients (n = 27) were in CR1 at time of allo-HSCT. Sixty-one percent (n = 20) had poor-risk cytogenetics, primarily B-ALL associated with t(9;22) in 18 patients. Twenty-one patients (8%) received post-transplant therapy for prevention of relapse, 17 with 5-azacitidine for highrisk myeloid disease and 4 with a tyrosine kinase inhibitor for Philadelphia chromosome-positive ALL.
Survival
At median 5 years' follow-up after the 1-year landmark (range 0.03-13 years), estimated 5-year RFS for the entire cohort was 73% (95% confidence interval (CI) 67-78%) and estimated 5-year OS was 76% (95% CI 70-81%) ( Figure 1 ). In comparison, in patients surviving to 100 days without relapse, 5-year RFS was 56% (95% CI Figure 1) . In AML, estimated 5-year RFS was 77% (95% CI 69-83%) and OS was 80% (95% CI 72-85%) after the 1-year landmark. For MDS, estimated 5-year RFS and OS were 70% (95% CI 57-80%) and 71% (95% CI 57-81%), respectively. Estimated 5-year RFS and OS in ALL were 62% (95% CI 42-76%) and 72% (95% CI 53-84%), respectively.
Graft-versus-host disease Before the 1-year landmark, 25 patients (9%) had developed grade I, 24 (9%) had developed grade II and 16 (6%) developed grade III-IV acute GvHD. The remaining 211 patients (76%) had no acute GvHD at 1 year. Of the patients with grade III-IV acute GvHD, three had received donor lymphocyte infusion, although all had some GvHD preceding donor lymphocyte infusion. One patient had developed acute GvHD 32 days after a CD34-selected cell boost. Eighteen patients (7%) had developed chronic GvHD before 1 year, with eight mild (3%), six moderate (2%) and four (1%) severe.
After the landmark, there were four cases (1%) of new acute GvHD, three of which followed a second allo-HSCT for relapse. None of these patients died of GvHD. Four patients (1%) developed new chronic GvHD after 1 year, which was mild in two patients and severe in two patients, of whom both died of GvHD. Recipients of mismatched donor grafts overall were at higher risk of grade ⩾ II acute GvHD or moderate-to-severe chronic GvHD, which developed in 14% of patients receiving grafts from HLA-matched donors and 23% of patients with mismatched donors (P = 0.05).
Non-relapse mortality There were 28 relapses after the landmark with an overall 5-year cumulative incidence of relapse of 11% (95% CI 7-15%): 15 in AML (9%, 95% CI 5-14%), 4 in ALL (13%, 95% CI 1-26%) and 9 in MDS (13%, 95% CI 4-21%). Median time to relapse in patients with disease recurrence after the landmark was 25 months posttransplant (range, 12-119 months). Among patients with relapse events, 11 were alive at last follow-up, including 6 who underwent second allo-HSCT. There were 46 deaths without relapse, with a 5-year cumulative incidence of NRM of 16% (95% CI 12-21%). Table 2 details causes of late mortality. GvHD, both acute and chronic, was the most common cause of death, accounting for 17 of 63 total deaths (27%), followed closely by relapse (n = 16, 25%) and infection (n = 12, 19%). Of deaths due to viral infection, two were attributed to EBV, two to JC virus and one to CMV. Six patients died of other malignancies, including three new cancers and three recurrences of unrelated cancers that had previously been in remission before transplant. In contrast, among patients excluded from the landmark analysis due to death or relapse before 1 year, relapse was the most common cause of death (n = 58 of 136 total deaths, 43%), followed by infection (n = 39, 29%; 15 viral, 14 bacterial, 2 parasitic, 1 fungal, 7 multiple/unknown), organ failure (n = 18, 13%), GvHD (n = 14, 10%), primary graft failure (n = 2, 1%) and other or unknown Long-term prognosis for 1-year RFS C Cho et al causes (n = 5, 4%). In these patients, deaths from viral infection were caused by Adenovirus (n = 5) in addition to EBV (n = 5) and CMV (n = 4).
Factors associated with late prognosis
In univariate analysis (Table 3) , increasing age (hazard ratio (HR) per 10 years 1.30, 95% CI 1.04-1.62, P = 0.02), Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) ⩾ 3 (HR 2.51, 95% CI 1.28-4.90, P = 0.007) and acute GvHD by 1 year (HR 2.32, 95% CI 1.39-3.88, P = 0.001; Figure 2 ), particularly grade III-IV (HR 5.61, 95% CI 2.81-11.22, P o0.0001), significantly correlated with poorer OS; similar associations were found for RFS. Chronic GvHD by 1 year did not significantly associate with RFS or OS. In multivariate analyses controlling for age, HCT-CI and grade of acute GvHD by 1 year, patients with HCT-CI scores of 3 or higher had significantly worse OS (HR 2.53, 95% CI 1.26-5.08, P = 0.009) and marginally worse RFS (HR 1.79, 95% CI 0.98-3.27, P = 0.06), compared with those with a score of 0. Patients with an HCT-CI score of 1-2 had a similar RFS and OS (Table 3, Figure 3 ). Increasing grades of acute GvHD were also associated with progressively worse RFS and OS by multivariable analysis (Table 3 and Figure 4) , with grade III-IV portending the worst prognosis. Use of chemotherapy-based conditioning correlated with poorer RFS but not OS on univariate analysis. This association was not significant on multivariable analysis (TBI HR 1.0 (reference); chemo HR 1.04, 95% CI 0.55-1.97, P = 0.90). There was no association detected between the method of CD34+ cell selection (ISOLEX versus CliniMACS) and RFS or OS. Table 4 shows results of univariate analysis of the effect of disease-related factors on survival. Intermediate-or high-risk AML correlated with marginally worse RFS on univariate analysis (P = 0.08), with HR of 5.16 for intermediate risk (95% CI 0.69-38.37, P = 0.11) and 7.98 for poor risk (95% CI 1.05-60.39, P = 0.04). The difference in OS was not significant (P = 0.25). Among patients with ALL, entering transplant in CR2 or with refractory disease significantly correlated with worse RFS compared with CR1, with HR 4.56 (95% CI 1.41-14.79, P = 0.01) and marginally correlated with poorer OS (HR 3.51, 95% CI 0.94-12.12, P = 0.06). In MDS, none of the evaluated disease features, including pre-HSCT disease status, cytogenetic risk or Revised International Prognostic Scoring System score at diagnosis or before HSCT, corresponded with a significant difference in RFS or OS.
DISCUSSION
This study demonstrates that patients who receive CD34+ cellselected allo-HSCT for AML, ALL or MDS and survive without relapse past 1 year have an excellent prognosis. The high probability of long-term RFS and OS, and low incidence of late relapse seen in our study meet or exceed those same outcomes in earlier landmark analyses of survivors of myeloablative allo-HSCT that did not distinguish between TCD and unmodified grafts. 11, 12 Most recently, Lee et al. 12 reported adult patients with acute leukemia who underwent allo-HSCT between 1990 and 2005, and were alive and relapse free at 1 year, noting a 5-year RFS of 78% in AML and 71% in ALL, similar to that seen in our cohort. Of note, the median ages of patients included in that prior analysis were 37 years in AML and 29 years in ALL, with a minority of patients over 50 years, in contrast to a median age of 54 years in this study population. Prior comparisons of CD34+ cell-selected allo-HSCT with unmodified grafts have likewise shown comparable survival between the two approaches despite older patient age in the CD34+ cell-selected cohorts. 8, 9 These results raise the possibility that CD34+ cell-selected allo-HSCTs might allow older patients to receive the antileukemic benefit of myeloablative conditioning without excessive risk of late mortality.
However, late mortality persists due to both relapse and NRM and we have identified risk factors that represent key areas of unmet need. Among patient-specific factors with prognostic significance, an HCT-CI score of 3 or greater correlated with poorer survival, a finding concordant with our analyses elsewhere Abbreviations: CI = confidence interval; HR = hazard ratio; HSCT = hematopoietic cell transplantation; IPSS-R = revised international prognostic scoring system; OS = overall survival; RFS = relapse-free survival.
Long-term prognosis for 1-year RFS C Cho et al of CD34+ cell-selected allo-HSCT for AML and MDS. 19 Also consistent with our prior findings, patients in this cohort with an HCT-CI score of 1-2 had similar long-term survivals to those with a score of 0. This indicates that the use of CD34+ cell selection attenuates late NRM in such patients with more modest comorbidity burdens compared with unmodified myeloablative allo-HSCT, and that such patients may be optimal candidates for consideration of CD34+ cell selected allo-HSCT. Further research should enhance our understanding of the influence exerted by comorbidities in the CD34+ cell selection setting, which will in turn optimize patient selection. Patients with more substantial comorbidities remain in need of additional strategies to attenuate NRM. Although CD34+ cell selection resulted in a low incidence of acute and chronic GvHD, those few patients who had developed acute GvHD at any time before 1 year, particularly grade III-IV, had a poor prognosis. GvHD, although uncommon after the 1-year landmark, was the most common cause of death. Even with CD34+ cell selection, the use of mismatched donor allografts and donor lymphocyte infusion in particular expose patients to heightened risk of GvHD. We did not detect a difference in survival for patients with chronic GvHD, which has been identified as a risk factor for late mortality in the previous Center for International Blood and Marrow Transplant Research landmark analyses. 11, 12 With very few patients with chronic GvHD, however, our sample was likely too small to detect a difference and, despite an extremely small number of patients with moderate to severe chronic GvHD before or after the 1-year landmark, a disproportionate number died of chronic GvHD or an acute/chronic GvHD overlap syndrome. Our data thus highlight the need for further strategies to recognize patients at heightened risk of both acute and chronic GvHD despite CD34+ cell selection, to diagnose GvHD at an earlier stage and to manage it effectively.
Infection, especially viral infection, was another major cause of late mortality, underscoring the role of post-transplant lymphopenia, which is more pronounced with CD34+ cell selection. 20, 21 Novel strategies to enhance immune reconstitution after CD34+ cell-selected allo-HSCT are indicated. 22 Of particular interest, as the use of CD34+ cell selection obviates the need for pharmacologic GvHD prophylaxis, it represents a suitable platform for the study and implementation of cell-and immune-based approaches to enhance post-transplant immunity without increasing risk of GVHD, including the use of cytotoxic lymphocytes directed against viral or leukemic antigens, checkpoint inhibitors and cytokinebased therapies.
The modest contribution of many disease-related factors including cytogenetic risk and remission status on long-term prognosis indicates that the effect of such variables recedes over time in patients who are able to survive without relapse past the initial post-HSCT period. Although our analysis was limited by incomplete data regarding pre-HSCT minimal residual disease, which portends a high risk of post-HSCT relapse in both AML and ALL, [23] [24] [25] this effect largely influences relapse earlier post transplant. The specific impact on late relapse remains unknown. We also lacked complete data on molecular markers in AML for the majority of patients, including the presence of FLT3, NPM1, CEBPA or c-kit mutations, due to the retrospective design of this analysis. Such information would have facilitated more complete risk stratification by contemporary methods and will be incorporated in future analyses.
Although encouraging, these retrospective findings require prospective confirmation. To this end, TCD is currently under investigation in a national phase III randomized trial, BMT CTN 1301 (NCT02345850), comparing CD34 selection with posttransplant cyclophosphamide versus standard GvHD prophylaxis with tacrolimus and methotrexate.
In summary, for the patient who undergoes CD34+ cell-selected PBSC transplant and is alive without disease at the 1-year landmark, long-term survival is excellent in the absence of substantial comorbidities and GvHD. Efforts to improve identification of patients at risk for late events and strategies to treat such patients, while taking advantage of the properties of the CD34+ cell selection platform, constitute vital areas of future research to improve even further on these outcomes.
